AstraZeneca announced a new investment in Canada to support the company’s move into a larger, more modern facility in Greater Toronto Area.

For people with atrial fibrillation (Afib), investigational abelacimab proved to be a potent dual factor XI/XIa inhibitor with much lower safety risks compared with a direct oral anticoagulant (DOAC), ...

In the Phase I dose escalation portion, which evaluated the combination in participants with small cell lung cancer, the first patient treated attained partial remission.

Monopar Therapeutics Inc . (NASDAQ:MNPR) stock soared to a 52-week high, reaching a price level of $38.91. According to ...

(Alliance News) - AstraZeneca PLC on Thursday announced a USD570 million investment in Canada, creating more than 700 jobs, across all areas of the business.